Here are the 424B prospectus supplements from newcleo plc (NWCL) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow NWCL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full NWCL filings page.
newcleo plc (NWCL) registers resale of up to 217,834,936 Ordinary Shares, issuance of up to 291,717 Ordinary Shares upon exercise of Company Private Warrants, and resale of approximately 8,855,000 Ordinary Shares issuable upon exercise of NextChem Warrants. Selling holders may sell at prevailing or privately negotiated prices. Newcleo receives no proceeds from resales, may receive proceeds from cash exercise of Company Private Warrants, and receives no cash from NextChem Warrant exercises, which are settled by set-off against earn-out obligations.
The registered resale shares equal 71.1% of outstanding Ordinary Shares as of October 16, 2026. Of these, 17,677,233 shares are not currently outstanding and are issuable only upon Class B conversion if volume weighted average price vesting conditions of $15.00 and $18.00 per share are met. None had been met, and they may never be. Potential sales could increase volatility or result in a significant decline in the public trading price.
Pre-combination historical results for the six months ended June 30, 2026 show revenue of €19.429 million versus €13.347 million in 2025 and a net loss of €81.981 million versus €74.293 million. Newcleo had not constructed LFR or MOX plants or entered binding customer contracts to operate them.